Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.
The US is partnering with Australia to boost rare earth production, aiming to reduce reliance on China. A $8.5 billion ...
Stigma, late diagnosis, and patchy access keep Europe from its HIV milestones. What will it take to close the gap?
The Project Phoenix event was facilitated by WORKit, a joint venture between South Waikato District Council (SWDC) and the ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...
Increased daily liveweight gain, respiratory health issues driven down by 75% and antibiotic use down 60% are the result of ...
The 2025 HBA India Leadership Summit is a two-day event aimed at advancing talent development and leadership. The theme for 2025, "Winning a Seat at the Table," will be explored in-depth by leading ...
Clinical Trials Arena on MSN
MSD’s HIV duo non-inferior to SoC in Phase III trials
M SD’s investigational two-drug HIV combination has been proven safe, efficacious and non-inferior to current standard of ...
Despite Wake's strong offensive performance, there was one glaring error in their tight loss to Georgia Tech that can certainly be improved this week. Despite ...
Rick Welts started his NBA journey as a Seattle SuperSonics ballboy in 1969 at the age of 16, moving up to serve as their ...
HBcAb-positive, HBsAg-negative people with HIV can safely switch from tenofovir-containing ART without clinically significant HBV reactivation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results